Post hoc analysis of the cluster randomized usual care versus caduet Investigation Assessing Long-term Risk (CRUCIAL) trial

Current Medical Research and Opinion

Volumn 29, Issue 6, 2013, Pages 589-596

  Hradec, Jaromír ^a   Zamorano, José ^b   Sutradhar, Santosh ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c PFIZER INC   (United States)

Author keywords

Caduet Investigation Assessing Long term Risk (CRUCIAL) trial; Framingham 10 year CHD risk; Global cardiovascular risk reduction; Single pill amlodipine atorvastatin (SPAA)

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; CHOLESTEROL; LIPID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PHYSICIAN; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY DISEASE; DRUG COMBINATIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS;

EID: 84877260055     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.783795     Document Type: Article

References (25)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
2. World Health Organization. Mortalities attributable to CHD or stroke, 2005. Available at: http://www.who.int/whosis/mort/download/en/index.html (Accessed August, 21 2012)
3. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209.
4. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. Geneva, Switzerland, 2007. Report No.: NLM classification: WG 120.
5. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
6. Sever PS, Poulter NR, Dahlöf B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm: extended observations 2 years after trial closure. Eur Heart J 2008;29:499-508.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-421.
8. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
9. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
10. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001.
11. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37.
12. Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J 2008;156:719-27.
13. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011;27:821-33.
14. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
15. Conroy RM, PyöräläK, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
16. Zamorano J, Erdine S, Lopez AP, et al. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010;122:7-15.
17. D'Agostino Sr RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.
18. Reissigova J, Zvarova J. The Framingham risk function underestimated absolute coronary heart disease risk in Czech men. Methods Inf Med 2007;46:43-9.
19. Marrugat J, Solanas P, D'Agostino R, et al. [Coronary risk estimation in Spain using a calibrated Framingham function]. Rev Esp Cardiol 2003;56: 253-61.
20. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673-81.
21. Hussein MA, Chapman RH, Benner JS, et al. Adherence to single-pill amlodipine/atorvastatin compared with two-pill amlodipine\+atorvastatin and other calcium channel blocker\+statin combinations among United States managed care enrollees. J Am Coll Cardiol 2007;49:288A.
22. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc Disord 2010;10:29.
23. Edelman D, Oddone EZ, Liebowitz RS, et al. A multidimensional integrative medicine intervention to improve cardiovascular risk. J Gen Intern Med 2006;21:728-34.
24. Vrablik M, Freiberger T, Lanska V, et al. [The Atractiv project: improvement of cardiovascular preventive in primary care in the Czech Republic]. Vnitr Lek 2008;54:1131-9.
25. Vale MJ, Jelinek MV, Best JD, et al. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the 'real world'-randomized controlled trial. J Clin Epidemiol 2002;55:245-52.